Gilead Sciences, Inc. (GILD)

NMS – Цена в реальном времени. Валюта: USD

127.88

+4.04 (3.26%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

127.48

-0.40 (-0.31%)

После закрытия: Jun 26, 2026, 7:23 PM EDT

16.06.2026

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

15.06.2026

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.

15.06.2026

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. “This filing reflects Gilead's continued commitment to advancin.

12.06.2026

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Ebola--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases.“At Gilead, we recognize the urgency and human toll of global health emergencie.

11.06.2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

11.06.2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, commun.

11.06.2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

Видео

19.03.2026

Positive

5 Stocks to Buy in a High-Risk Bull Market

27.02.2026

Positive

Johanna Mercier on Gilead's HIV prevention innovation

12.01.2026

Positive

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

21.10.2025

Neutral

Final Trade: F, HAL, MA, GILD

Пресс-релизы

15.06.2026

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

12.06.2026

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

11.06.2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

08.06.2026

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in.

Gilead Sciences, Inc. (GILD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Gilead Sciences, Inc. (GILD)

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Видео

Пресс-релизы

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Видео

Пресс-релизы

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Search stocks

Gilead Sciences, Inc. (GILD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Gilead Sciences, Inc. (GILD)

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Видео

Пресс-релизы

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Видео

Пресс-релизы

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment